N-Methyl-PPPA

N-Methyl-PPPA

N-Methyl-PPPA
Systematic (IUPAC) name
N-Methyl-3-phenoxy-3-phenyl-1-propanamine
Identifiers
ATC code None
Synonyms Detrifluoromethylfluoxetine
Chemical data
Formula C16H19NO
Molecular mass 241.328 g/mol

N-Methyl-PPPA, or N-methyl-3-phenoxy-3-phenylpropan-1-amine, is a serotonin-norepinephrine reuptake inhibitor (SNRI) which was developed by Eli Lilly from diphenhydramine in the early 1970s while in search of new antidepressants, but was never marketed.[1][2][3] It is closely related structurally to fluoxetine, atomoxetine, and nisoxetine.[1][2][3]

See also

References

  1. ^ a b Francisco Lopez-Munoz; Cecilio Alamo (9 September 2011). Neurobiology of Depression. CRC Press. pp. 132–.  
  2. ^ a b Walter Sneader (31 October 2005). Drug Discovery: A History. John Wiley & Sons. pp. 416–417.  
  3. ^ a b Wong DT, Bymaster FP, Engleman EA (1995). "Prozac (fluoxetine, Lilly 110140), the first selective serotonin uptake inhibitor and an antidepressant drug: twenty years since its first publication". Life Sci. 57 (5): 411–41.